Mymetics Announces Discontinuation of the RSV Collaborative Project

Mymetics Corporation (OTCQB:MYMX) announced that its subsidiary Bestewil Holding BV, has received notice from RSV Corporation (RSVC) that it will no longer pursue the development of a vaccine technology for Respiratory Syncytial Virus (RSV) in order to focus on other infectious therapies. On December 27, 2013, Mymetics and RSVC, funded by Astellas Pharma Inc., had announced the signature of a License and Collaboration Agreement focusing on RSV, which will now formally be terminated as of July 25, 2016.
According to George Siber, MD Chief Scientific Officer of RSVC:

Due to fast evolving market dynamics in the RSV vaccine market and in particular the development by several major pharma companies of promising candidates already at clinical stage, we have decided to focus our priorities on other areas and therapeutic needs. We’re very appreciative of the efforts by the Mymetics team to advance the project.

Ronald Kempers, CEO of Mymetics commented:

While being terminated, this partnership has nevertheless allowed Mymetics to further strengthen its know-how and expertise in the RSV field and enveloped viruses. We will build on this to create additional value for virosome based vaccines for infectious diseases. Separately from the collaboration with RSVC, we are developing in particular several other product candidates in the fields of HIV, Malaria and intra-nasal flu, all of which have recorded very promising results. In addition, we will be starting the development of a vaccine for Chikungunya and have started to investigate Zika.

Click here to view the full press release.